Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences Ltd. director Melissa B. Epperly exercised options for 17,750 common shares on October 1, 2026, at $4.46 per share. She sold 16,850 shares at a weighted-average $36.08 per share (range $35.46–$36.45) and 900 shares at a weighted-average $36.57 per share (range $36.48–$36.72), under a Rule 10b5-1 trading plan adopted March 30, 2026. Her reported stock-option balance following the transaction was 151,416 options.
Roivant Sciences Ltd. CEO Matthew Gline reported the disposition of 76,171 Common Shares on September 30, 2026, as part of the issuer’s net settlement of previously granted RSUs to satisfy applicable tax withholding obligations upon vesting and settlement. The reported price was $36.57 per share, and his direct holdings following the transaction were 16,583,774 Common Shares.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti acquired 40,309 common shares through the issuer’s net settlement of previously granted RSUs on September 30, 2026, to satisfy applicable tax withholding obligations. The reported price was $36.57 per share; Frank Torti held 13,495,893 common shares following the transaction. No Rule 10b5-1 plan is reported.
Roivant Sciences Ltd. President & CIO Mayukh Sukhatme had 46,879 common shares withheld through issuer net settlement on September 30, 2026, to satisfy tax withholding obligations tied to the vesting and settlement of previously granted RSUs. The reported price was $36.57 per share. He directly held 18,583,860 common shares following the transaction.
Roivant Sciences Ltd. officer Eric Venker, whose title is President & Immunovant CEO, exercised options for 200,000 common shares at a $3.85 per-share exercise price and sold 200,000 common shares on September 30, 2026. The shares were sold at a weighted average price of $36.62 per share in multiple transactions ranging from $36.49 to $36.76; the sales were made under a Rule 10b5-1 trading plan adopted on March 28, 2025. After the exercise, the reported direct stock-option position was 3,644,834 shares.
Roivant Sciences Ltd. officer Eric Venker reported a proposed sale of 200,000 common shares through Rockefeller Financial LLC, with an aggregate market value of $7,323,556.00. The stated sale date is September 30, 2026, and the shares are to be sold under a Rule 10b5-1 trading plan adopted March 28, 2025.
Roivant Sciences Ltd. (ROIV) reports that Chief Accounting Officer Jennifer Humes had 3,880 Common Shares withheld on September 20, 2026, at $39.77 per share to satisfy tax withholding obligations upon vesting and settlement of previously granted RSUs. After this tax-withholding disposition, she directly holds 106,419 Common Shares, which include shares acquired under the company’s Employee Stock Purchase Plan. No transactions are reported as made under a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. (ROIV) reported that Chief Financial Officer Richard Pulik had 2,129 common shares withheld on September 20, 2026 to satisfy tax withholding obligations upon vesting of previously granted RSUs. The transaction was a net share settlement, not an open-market sale, and left him holding 269,681 common shares directly.
Roivant Sciences Ltd. (ROIV) reported that director Keith S. Manchester received equity compensation on September 16, 2026. He was granted 5,054 Common Shares in the form of restricted stock units and stock options for 10,531 Common Shares at an exercise price of $39.57 per share.
Both the RSUs and options are scheduled to vest 100% on September 16, 2027, subject to his continued service as a director. After the RSU grant, he directly holds 1,753,457 Common Shares. The options expire on September 15, 2036, and no Rule 10b5-1 trading plan is reported.
Roivant Sciences Ltd. (ROIV) reported that director Daniel Allen Gold received equity awards on September 16, 2026. He was granted 10,531 stock options to purchase Common Shares at an exercise price of $39.57 per share, expiring September 15, 2036, and an annual award of 5,054 RSUs, all vesting 100% on September 16, 2027, subject to continued board service. Following these grants, he directly holds 8,965,815 Common Shares. No Rule 10b5-1 trading plan is reported.